Department of Gynecology & Obstetrics, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Pathology, Weifang People's Hospital, Weifang, China.
J Int Med Res. 2020 Jun;48(6):300060520926742. doi: 10.1177/0300060520926742.
Patients with ovarian cancer are often in a hypercoagulable state and have a high risk of venous thrombosis, including deep vein thrombosis and pulmonary embolism. However, arterial thrombosis is relatively rare in ovarian cancer. We report a case a 46-year-old woman with ovarian clear cell carcinoma who developed arterial and venous thrombosis in the lower extremities as the first manifestation. Her arterial thrombosis-related ischemic symptoms were not responsive to anticoagulant treatment of low-molecular-weight heparin, but improved after neoadjuvant chemotherapy and surgery. Therefore, we hypothesize that the optimal therapy for arterial thrombosis in ovarian cancer is treatment for the underlying disease (i.e., ovarian cancer). A thorough investigation is required to determine the relationships between arterial thrombosis and ovarian cancer and antithrombotic treatments for ovarian cancer related-arterial thrombosis.
卵巢癌患者通常处于高凝状态,静脉血栓形成风险高,包括深静脉血栓形成和肺栓塞。然而,卵巢癌中的动脉血栓形成相对少见。我们报告了一例 46 岁女性,患有卵巢透明细胞癌,以下肢动脉和静脉血栓形成为首发表现。她的动脉血栓形成相关的缺血症状对抗凝治疗(低分子量肝素)无反应,但在新辅助化疗和手术后得到改善。因此,我们假设卵巢癌中动脉血栓形成的最佳治疗方法是治疗基础疾病(即卵巢癌)。需要进行彻底的调查,以确定动脉血栓形成与卵巢癌之间的关系以及卵巢癌相关动脉血栓形成的抗血栓治疗。